echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Haizheng pharmaceutical "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection" obtained clinical approval

    Haizheng pharmaceutical "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection" obtained clinical approval

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    According to the website of the State Food and Drug Administration (CFDA), the approval status of "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection", a clinical heavyweight McAb drug declared by Haizheng pharmaceutical, has changed to "approved pending"

    The drug is a generic of rituxan, a blockbuster product of Roche's monoclonal antibody, which mainly treats lymphoma and rheumatoid arthritis

    Rituxan is the world's first monoclonal antibody approved for clinical treatment of non Hodgkin's lymphoma (NHL)

    According to the statistics of evaluatepharma, a global pharmaceutical market forecasting agency, the global sales of rituxan in 2010-2012 were 5.034 billion US dollars, 6.14 billion US dollars and 7.143 billion US dollars, respectively

    At present, there are no domestic enterprises to produce the product

    Apart from Haizheng pharmaceutical, there are only five domestic enterprises applying for the clinical application of the product

    Haizheng pharmaceutical industry began to distribute monoclonal antibodies in 2006

    Up to now, it has declared three heavyweight products, and another two are generic drugs of ambrano and adalimumab

    Ambrano, the fastest growing one, has declared production in July last year and is expected to be approved this year

    The McAb industry has high barriers to entry, significant clinical treatment effect, and extremely broad market prospects, which is easy to produce heavy bomb products

    In order to realize the transformation of the company to the field of McAb, in addition to the products that have been declared, the company has a echelon of reserve products in the future

    Baihua, chairman of Haizheng pharmaceutical, previously said that McAb is an important part of the company's R & D and one of the driving forces behind the company's subsequent performance

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.